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 Drug-induced liver injury (DILI) remains the most common 
cause of acute liver failure (ALF) in the western world. Exclud-
ing paracetamol overdose, nearly all DILI encountered in the 
clinical setting is idiosyncratic in nature because affected 
individuals represent only a small proportion of those treated 
with such drugs. In many cases, the mechanism for idiosyn-
crasy is immune-mediation and is often identiﬁ ed by genetic 
risk determined by human leukocyte antigen variants. In the 
absence of diagnostic tests and/or biomarkers, the diagnosis 
of DILI requires a high index of suspicion after diligently 
excluding other causes of abnormal liver tests. Antibiotics are 
the class of drugs most frequently associated with idiosyn-
cratic DILI, although recent studies indicate that herbal and 
dietary supplements are an increasingly recognised cause. It is 
imperative that upon development of DILI the culprit drug be 
discontinued, especially in the presence of elevated transami-
nases (aspartate aminotransferase/alanine aminotransferase 
ratio ≥5 times the upper limit of normal) and/or jaundice. Risk 
factors for the development ALF include hepatocellular DILI 
and female gender, the treatment being supportive with some 
beneﬁ t of N-acetylcysteine in the early stages. In view of the 
poor transplant-free survival in idiosyncratic DILI, early consid-
eration for liver transplant is mandatory. 
 KEYWORDS :  Autoimmune hepatitis ,  cholestasis ,  drug-induced 
acute liver failure ,  herbal and dietary supplements ,  hepatocellular 
DILI ,  hepatotoxicity 
 Introduction 
 At a regulatory level, drug-induced liver injury (DILI) is the 
commonest reason for withdrawing drugs from the market 
and/or issuing warnings and modification of use. 1 DILI is 
classified as either predictable or unpredictable (idiosyncratic). 2 
The former tends to be dose-related, has a short latency (days), 
is due to direct toxicity of the drug or its metabolite, and is 
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reproducible in animal models (eg paracetamol overdose). 3 
The vast majority of DILI, however, is idiosyncratic or 
unpredictable – it is unexpected based on the pharmacological 
actions of the drug and in most cases routine animal toxicology 
fails to identify the risk of subsequent clinical toxicity. 4 This 
review shall largely focus on idiosyncratic DILI . 
 Epidemiology 
 Idiosyncratic DILI is an uncommon adverse event when taking 
prescription or non-prescription medications. It is difficult to 
assess the true incidence of DILI because of different diagnostic 
criteria and under reporting. 5 However, recent population-
based studies estimate the incidence to vary between 13.9–19.1 
cases per 100,000 people per year. 5,6 
 Data from prospective DILI registries suggest that antibiotics 
remain the most common cause of idiosyncratic DILI. The 
American DILI Network (DILIN) reported antibiotics to be 
implicated in 45.4% of cases. 7 Other common drug classes 
reported by the American DILIN were herbal and dietary 
supplements (HDS; 16.1% – a significant increase over the last 
10 years), cardiovascular agents (9.8%), central nervous system 
agents (9.1%), anti-neoplastic agents (5.5%) and analgesics 
(3.7%). 7 Amoxicillin-clavulanate is the most common 
individual drug implicated in DILI as confirmed by both 
European and American studies (Table  1 ). 6–10 In some Asian 
countries, however, HDS are implicated in more than 70% of 
all DILI. 11 
 DILI includes the whole spectrum from asymptomatic 
elevation in liver tests to acute liver failure (ALF). In fact, 
DILI remains the most common cause of ALF in the UK 12 
and USA. 13 Specifically, in the UK, paracetamol overdose 
causes approximately 57% of all ALF with non-paracetamol 
drugs accounting for a further 11%. 12 In idiosyncratic 
DILI, approximately 4% progress to ALF; risk factors are 
female gender (70%) and hepatocellular DILI (80%). 8 The 
drugs most commonly implicated in ALF include anti-
tuberculosis therapies (ATT), HDS, sulpha-containing drugs, 
nitrofurantoin, phenytoin, sodium valproate, flutamide and 
amoxicillin-clavulanate. 8,14 
 Types of DILI 
 Idiosyncratic DILI can be classified according to the pattern 
of liver tests observed – hepatocellular, cholestatic, or mixed. 
This classification was first established by the Council for 
International Organizations of Medical Sciences (CIOMS) 15 
and has recently been modified by the US Food and Drug 
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Administration (FDA) Drug Hepatotoxicity Steering 
Committee. 16 Hepatocellular DILI is characterised by an alanine 
aminotransferase (ALT) ≥3 times the upper limit of normal 
(ULN) and ALT/alkaline phosphatase (ALP) ratio ≥5 times 
ULN; cholestatic DILI by an ALP ≥2 times ULN and ALT/ALP 
ratio of ≤2 times ULN; and mixed DILI with ALT ≥3 times 
ULN, ALP ≥2 times ULN and ALT/ALP ratio <5 but >2 times 
ULN. Individual drugs have dispositions toward a characteristic 
clinical signature; however, exceptions do occur. For example, 
amoxicillin-clavulanate usually results in a cholestatic injury but 
less frequently has also been associated with ALF. 17,18 
 Another way to classify idiosyncratic DILI is as immune-
mediated (allergic) or non-immune mediated (non-
allergic). 19 If immune-mediated, the latency is shorter 
(1–6 weeks) compared with non-immune mediated reactions 
(1 month to 1 year). 1,20 However, exceptions do occur 
with immune reactions appearing after a very long latency 
with drugs such as nitrofurantoin 21 or even after drug 
cessation (eg sulfonamides, erythromycin and amoxicillin-
clavulanate). 20 Immune-mediated idiosyncratic reactions 
can be characterised by presence of fever, rash, eosinophilia, 
autoantibodies (such as antinuclear and anti-smooth muscle 
antibodies) and Stevens-Johnson syndrome. Non-immune 
mediated reactions lack the aforementioned characteristics 
and importantly, as described, tend to have a long latency 
period (1 month to 1 year). 1,4,20 
 Other forms of DILI include steatohepatitis (amiodarone, 
tamoxifen, methotrexate), 22  neoplasms (hepatic adenomas due 
to androgenic anabolic steroids (AAS)), 23 and vascular (nodular 
regenerating hyperplasia due to azathioprine). 24 
 Risk factors 
 Multiple factors have been found to be associated with an 
increased susceptibility to idiosyncratic DILI. The American 
DILIN found a higher prevalence of DILI in women (59% 
female versus 41% male), 7 although this was not corroborated 
by the Spanish DILI registry (49% female versus 51% male). 8 
Potential reasons for increased female susceptibility to DILI 
include differences in various aspects of drug pharmacokinetics 
or pharmacodynamics; hormonal effects or interactions 
with immunomodulating agents or signaling molecules; and 
differences in the adverse response of the immune system 
to some drugs, reactive drug metabolites or drug-protein 
adducts. 25 It is consistently observed, however, that women tend 
to be younger and develop hepatocellular DILI whereas men 
tend to be older and develop cholestatic DILI. 7,26 
 Older patients have an almost threefold increase in the 
incidence of DILI as shown in a study from Iceland. 6 This was 
attributed to the increased prescription rate of drugs in older 
patients. 6 In general, higher drug dose and longer duration of 
therapy have also been implicated in poorer outcomes. 26–28 In 
the Spanish Registry, 77% of patients with idiosyncratic DILI 
received medications with daily doses of ≥50 mg. 26 Ninety 
percent of patients with serious DILI needing a liver transplant 
and reported to the Swedish Adverse Drug Reactions Advisory 
Committee were consuming ≥50 mg/day of the drug. 27 A 
longer duration of drug therapy (135±31 days versus 53±3 days, 
p<0.0001)has been associated with a higher liver-related 
morbidity and mortality. 29 
 It remains controversial as to whether pre-existing liver 
disease increases susceptibility to idiosyncratic DILI. In the 
American DILIN, 10% of patients with DILI had pre-existing 
liver disease, mostly due to hepatitis C and non-alcoholic 
fatty liver disease (NAFLD). This group was characterised by 
more severe liver injury and higher overall mortality (16% 
verus 5.2%, p<0.001) although they had similar liver-related 
mortality (57% versus 46%, p=0.5). 7 The higher overall 
mortality in those with pre-existing liver disease may have 
been due to significantly higher prevalence of comorbidities, 
specifically diabetes mellitus (38% versus 23%, p=0.004). 7 
Additionally, alcohol excess and/or risk factors for NAFLD 
increase susceptibility to methotrexate toxicity by three- to 
fourfold. 30 Furthermore, some studies have shown that 
patients with chronic hepatitis B or C could have a threefold 
increased risk of abnormal liver tests after receiving ATT. 31,32 
Nonetheless, the interpretation of liver injury in patients with 
chronic hepatitis B and C receiving ATT remains complex. It 
could be due to ATT-induced DILI, viral reactivation and/or 
immune reconstitution. 33 
 Genetic factors also increase susceptibility to DILI. For 
example, human leukocyte antigen (HLA) B*5701 confers an 
eightyfold increased risk to flucloxacillin induced DILI, whereas 
the absence of this genotype has an 88% negative predictive 
value for flucloxacillin-related DILI. 34 
 In case 1 (Box 1), we present a patient who could be 
considered to have flucloxacillin hepatotoxicity. However, 
unusual features were the young age, short duration of drug 
use and near normal gamma-glutamyl transferase despite 
significant hyperbilirubinaemia. A more detailed history 
revealed the use of the dietary supplement Massdrol (which 
is an AAS) prior to ingestion of flucloxacillin. A subsequent 
liver biopsy revealed bland cholestasis characteristic of AAS 
hepatotoxicity (Fig  1 ). 35 His HLA genotype was B12/B42. HLA 
 Table 1.  Common drugs implicated in idiosyncratic drug-induced liver injury according to studies from 
different countries 
Iceland 6 American DILIN 7 Spanish registry 8 UK 9 
Amoxicillin-clavulanate Amoxicillin-clavulanate Amoxicillin-clavulanate Amoxicillin-clavulanate
Diclofenac Isoniazid Isoniazid Diclofenac
Azathioprine Nitrofurantoin Combined anti-tuberculous therapy Tricyclic antidepressants
Infliximab Trimethoprim-sulfamethoxazole Flutamide Macrolides
Nitrofurantoin Minocycline Ibuprofen Chlorpromazine
 DILIN = drug-induced liver injury network 
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(9% versus 4%, p<0.001). 7 Furthermore, use of non-body 
building HDS was associated with a significantly higher need 
for liver transplant compared with conventional drugs (13% 
versus 3%, p<0.05). 38 Worryingly, 7% of cases were attributed 
to HDS during the first 2 years of the American DILI registry 
compared with 20% 10 years later. 38 The American Acute 
Liver Failure Study Group (ALFSG) also recently reported 
that the prevalence of DILI-ALF/acute liver injury cases 
due to HDS increased between 1998–2007 and 2007–2015 
(12.4 versus 21.1%, p=0.047). The HDS group had higher 
transplantation rates (56% versus 32%, p<0.005) and lower 
transplant-free survival (17% versus 34%, p=0.044) compared 
with those receiving conventional drugs. 39 
 Specifically in hepatocellular DILI, a serum bilirubin of 
≥3 times ULN in the absence of biliary obstruction or Gilbert’s 
syndrome is associated with a mortality of approximately 10% 
(range 5–50%). 40 This is also known as Hy’s law, in recognition 
of the pioneering work done by Hyman Zimmerman – an 
American hepatologist. Hy’s law has now been confirmed by 
European and American prospective DILI registries. 7,8 Hy’s law 
has also been adopted by the US FDA as a predictor of severe 
DILI during clinical trials, although in the interest of patient 
safety the FDA has lowered the hyperbilirubinaemia required 
to ≥2 times ULN (‘modified Hy’s Law’). 40 The US FDA states 
that ‘finding one Hy’s law case in the clinical trial database is 
worrisome; finding two is considered highly predictive that 
the drug has the potential to cause severe DILI when given to a 
larger population’. 40 
 Predicting those who are likely to develop ALF in 
idiosyncratic DILI is difficult and even the application of Hy’s 
law provides a specificity of only 44–67% and sensitivity of 
83–90%. 8 In an attempt to improve this, the Spanish DILIN 
developed a composite score to predict ALF: AST ≥17.3 times 
 Fig 1.  Haematoxylin and eosin stain showing bland cholestasis due 
to androgenic anabolic steroid use with bile staining of hepatocytes 
(arrow) and Kupffer cell cytoplasm. Original magniﬁ cation 200x . Reprinted 
with permission from El Sherrif  et al . 35 
 Box 1.  Three cases of drug-induced liver injury – 
what is the diagnosis and management? 
 Case 1 
A 33-year-old male was admitted with a 2-week history of 
jaundice. He had been prescribed a 5-day course of flucloxacillin 
3 weeks previously for an ingrown toenail.
Investigations demonstrated bilirubin 120 μmol/L (peak 
614 μmol/L), AST 244 iu/L, ALT 312 iu/L, ALP 130 iu/L, γGT 72 iu/L 
and INR 1.0. Liver screen, including viral serology and imaging, 
were unremarkable.
 Case 2 
A 62-year-old female was referred for abnormal liver tests: ALT 
125 iu/L, ALP 245 iu/L. On examination, she had stigmata of 
chronic liver disease, and further investigation revealed a positive 
anti-smooth muscle antibody and elevated immunoglobulins, 
specifically IgG. Imaging confirmed cirrhosis. She had 
commenced a statin 1 year previously.
 Case 3 
A 55-year-old male, co-infected with the hepatitis B (inactive 
carrier) and hepatitis C virus, was 4 months into a 6-month 
course of pegylated interferon alpha and ribavirin. He was 
non-cirrhotic and thus far had shown an excellent response to 
antivirals with a normal liver panel and negative hepatitis B 
and C PCR. He was subsequently prescribed a 7-day course of 
clarithromycin for a chest infection and presented a week later 
with jaundice and confusion.
Investigations demonstrated bilirubin 350 μmol/L, ALT 2000 iu/L 
and INR 3.0. Liver screen, including viral PCR and imaging, were 
unremarkable.
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; INR = international normalised ratio; PCR = polymerase 
chain reaction; γGT = gamma-glutamyl transferase
B*5701, which confers susceptibility to flucloxacillin-related 
hepatotoxicity, 34 was not identified. 
 Pathogenesis 
 The pathogenesis of idiosyncratic DILI remains unknown but 
is most likely due to a complex interplay between drug (eg 
dose, duration of therapy, hepatic metabolism, lipophilicity) 
and host factors (eg age, gender, genetic polymorphisms). The 
drug may form a reactive metabolite that triggers DILI or may 
form covalent adducts with tissue proteins, eliciting an immune 
response and subsequent DILI. 36,37 
 Natural history of DILI, and Hy’s Law 
 In the American DILIN, the presentation of DILI was 
with jaundice in 70% of cases. Most recovered after drug 
withdrawal; however, 17% progressed to chronic DILI 
(defined as abnormal liver tests for longer than 6 months) 
and 10% needed a liver transplant and/or died. 7 Mortality 
increased to 44% in the presence of Stevens-Johnson 
syndrome. 7 Compared with those with cholestatic DILI, those 
with hepatocellular DILI were more likely to require a liver 
transplant (6.2% versus 2.9%, p<0.001) and have fatal injury 
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ULN; total bilirubin ≥6.6 times ULN; and AST:ALT ≥1.5 times 
ULN. These criteria are able to determine progression to 
ALF with a specificity of 82% and sensitivity of 80%. 8 This 
composite score, however, needs to be validated in additional 
prospective studies. 
 Diagnosis 
 Since there are no diagnostic tests or biomarkers for 
idiosyncratic DILI, its diagnosis is made after stringently 
excluding other causes of liver disease, assessing the temporal 
association between use of drug and abnormal liver tests, 
looking for a characteristic clinical drug signature, and 
assessing improvement in liver tests upon drug withdrawal. 
Drug re-challenge is rarely indicated and cannot be advocated 
on ethical grounds. Nonetheless, one situation where a re-
challenge may be justifiable is in the treatment of tuberculosis; 
however, this must only be done after carefully weighing the 
risks and benefits and in close liaison with a hepatologist. 4 
Finally, various causality assessment tools exist for DILI, of 
which the Roussel Uclaf Causality Assessment Method is the 
most used although it is far from perfect. 41 
 Liver biopsy can be helpful in certain situations, particularly 
to exclude other causes of liver disease (eg alcohol, NAFLD). It 
also has a role if ‘drug-induced’ autoimmune hepatitis (AIH) 
is suspected and needs differentiating from idiosyncratic 
DILI. 42 Portal and intra-acinar plasma cells, rosette formation 
and emperiopolesis are histological features that favour 
AIH (p<0.02), whereas portal neutrophils and intracellular 
(hepatocellular) cholestasis are more prevalent in DILI 
(p<0.02; Table  2 ). 42 Nonetheless, this differentiation is based 
on retrospective data and, in the real world, differentiating 
‘drug-induced AIH’ from idiosyncratic DILI may be far more 
difficult. 
 In case 2 (Box 1), a subsequent liver biopsy confirmed 
cirrhosis with lymphoplasmacytic portal inflammation and 
interface hepatitis. This was suggestive of AIH. While statins 
have been associated with DILI, including ‘drug-induced’ 
AIH, 43 it would have been very unusual for the statin to result 
in cirrhosis, especially within a year. 43 This patient most likely 
had an underlying propensity to develop idiopathic AIH 
and the statin either unmasked or triggered this, or was an 
innocent bystander. She was treated with corticosteroids and 
azathioprine with good response. 
 Management of DILI 
 Prompt cessation of the culprit drug as soon as DILI is 
suspected is of paramount importance. There are also therapies 
for specific causes of DILI; for example, N-acetylcysteine (NAC) 
for paracetamol overdose 44 and L-carnitine for valproic acid 
overdose. 45 
 Corticosteroid therapy in DILI has a limited role and is 
reserved for those with immune-mediated DILI or ‘drug-
induced’ AIH. The former may only need a short course of 
steroids, whereas the latter, which is often indistinguishable 
from idiopathic AIH, often requires prolonged courses of 
steroids and/or additional immunosuppression. 46–49 As already 
stated, differentiating DILI from ‘drug-induced’ AIH can often 
be difficult and in such situations, after careful assessment of 
risks and benefits, a trial of corticosteroids may be warranted. 
Although ursodeoxycholic acid is often used in cholestatic 
DILI, its use remains non-evidence based. 50 
 Acute liver failure 
 Case 3 (Box 1) presents a patient who has developed ALF. 
Pegylated interferon alpha use has not been associated with 
ALF. Hepatitis B and C flares were excluded by negative 
polymerase chain reaction; therefore, the most likely 
cause was clarithromycin-induced ALF. Clarithromycin 
has been associated with cholestatic DILI, particularly in 
older patients, and ALF has been reported. 51 This patient 
was urgently listed for a liver transplant but unfortunately 
developed progressive cerebral oedema and died before he 
could receive a transplant. 
 Spontaneous survival with ALF secondary to idiosyncratic 
DILI (non-paracetamol) is poor with only 27.1% of patients 
alive at 3 weeks, 14 in contrast to paracetamol-induced ALF 
where spontaneous survival is 64–66%. 52 Therefore, it is 
crucial that, especially in idiosyncratic DILI, early discussion 
with a tertiary liver centre takes place at the first hint of ALF 
(worsening jaundice, coagulopathy (international normalised 
ratio >1.5) or development of hepatic encephalopathy (HE)). 
With transplantation the overall survival increases to 66.2%, 
which demonstrates the necessity to rapidly identify those with 
ALF due to idiosyncratic DILI. 8 The King’s College criteria are 
most commonly used to prioritise patients with paracetamol 
and idiosyncratic DILI for liver transplant. 53,54 
 Two earlier randomised controlled trials (RCTs) showed no 
benefit of corticosteroids in ALF and even demonstrated a 
poorer outcome in those with DILI. 55,56 A more recent study 
from the ALFSG corroborated this, showing no improvement in 
overall survival in drug-induced, indeterminate or autoimmune 
ALF (61% versus 66%, p=0.41). 57 In fact, lower survival was 
observed in those patients with the highest model for end stage 
liver disease scores (>40) after corticosteroid therapy (30% 
versus 57%, p=0.03). 57 
 Table 2.  Comparison of idiosyncratic DILI, ‘drug-
induced’ autoimmune hepatitis and idiopathic 
autoimmune hepatitis 46–49 
 Idiosyncratic 
DILI 
‘Drug 
induced’ AIH 
Idiopathic 
AIH 
 Histology Portal 
neutrophils, 
intracellular 
cholestasis
Interphase 
hepatitis, 
plasma cells
Interphase 
hepatitis, 
plasma cells, 
emperipolesis, 
rosettes
 Rash, 
eosinophilia 
+/− +/− −
 Fibrosis +/− + ++
 Response to 
steroids 
− + +
 Relapse 
on steroid 
withdrawal 
− +/− +
 AIH = autoimmune hepatitis, DILI = drug-induced liver injury 
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 NAC has a well-established role in paracetamol-induced 
ALF 44 although it is now also recommended in selected 
cases of non-paracetamol ALF. A 2009 RCT in patients with 
non-paracetamol ALF demonstrated similar 3-week survival 
for patients given NAC versus placebo (70% versus 66%, 
p=0.283). 58 However, transplant-free survival was significantly 
better for patients who received NAC compared with placebo 
(40% versus 27%, p=0.043), but this was confined to those with 
early HE (52% versus 30%, p=0.010); whereas those with grade 
3–4 HE had no benefit with NAC (9% versus 22%, p=0.912). 58 
DILI was the most prevalent aetiology of ALF within this study. 
 Conclusion 
 DILI includes the whole spectrum from asymptomatic and 
transient elevation in liver tests to ALF. DILI due to paracetamol 
overdose and idiosyncratic drug reactions remain the most 
common causes of ALF in the western world. DILI is a diagnosis 
of exclusion and there is an urgent need to develop diagnostic 
biomarkers. Antimicrobials remain the most common cause of 
idiosyncratic DILI although recent studies show a significant 
increase in DILI due to herbal and dietary supplements. 
Hepatocellular DILI is more likely to progress to ALF compared 
with cholestatic or mixed DILI. The management of DILI is 
symptomatic with prompt cessation of the culprit drug and 
early referral for liver transplant upon the development of ALF, 
especially in those with idiosyncratic DILI. ■
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